Stay updated with breaking news from Nuclear Enriched Transcript Sort. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
)
Boston US life science company Cerevance, which has facilities at Cambridge Science Park, has taken its Series B-1 round to a stunning $98 million after securing a $47m extension.
Positive CVN424 Phase 2 data for Parkinson’s disease to be presented Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Partnership will focus on the discovery of novel targets in Alzheimer’s disease - News - PharmaTimes
Merck is paying $25 million to kick off a research partnership with Cerevance, a startup that analyzes donor brain tissue to find novel targets for new neurological disorder drugs. While Cerevance’s lead program is a Parkinson’s disease drug, Merck is wants to see if the startup’s technology can help it discover and develop new Alzheimer’s disease drugs.